8-K Announcements
6Material company update
Apr 22, 2026·SEC
Material company update
Apr 14, 2026·SEC
Material company update
Mar 18, 2026·SEC
Hepion Pharmaceuticals, Inc.(HEPA)Earnings, Financials & Key Ratios
HEPA•NASDAQ
Price updated Jun 19, 2026
AboutHepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.Show more
- Revenue$0
- EBITDA-$8M+57.3%
- Net Income-$8M+37.3%
- EPS (Diluted)-0.88+99.2%
- ROE-2058.63%-322.7%
HEPA Key Insights
Hepion Pharmaceuticals, Inc. (HEPA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y profit CAGR of 16.5%
- ✓Momentum leader: RS Rating 86 (top 14%)
- ✓Trading at only 0.2x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when HEPA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
HEPA Price & Volume
Hepion Pharmaceuticals, Inc. (HEPA) stock price & volume — 10-year historical chart
Loading chart...
HEPA Growth Metrics
Hepion Pharmaceuticals, Inc. (HEPA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM81.86%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM99.69%
Return on Capital
10 Years-195.89%
5 Years-253.69%
3 Years-387.75%
Last Year-671.34%
HEPA Peer Comparison
Hepion Pharmaceuticals, Inc. (HEPA) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MDGL | 11.66B | 505.75 | -39.36 | 432.05% | -27.32% | -50.15% | 0.59 | |
 AKRO | 4.5B | 54.65 | -14.57 | -30.58% | 0.05 | |||
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 TERN | 4.77B | 52.95 | -51.41 | -20.02% | 0.00 | |||
 ELVN | 2.75B | 45.10 | -24.64 | -21.04% | 0.00 | |||
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 GNFT | 447.53M | 8.95 | 256.88 | 134.56% | -14.12% | -22.98% | 0.90 | |
 HIMS | 7.79B | 35.47 | 69.55 | 59% | -0.56% | -2.48% | 2.34 |
Compare HEPA vs Peers
Hepion Pharmaceuticals, Inc. (HEPA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
HEPA Income Statement
Hepion Pharmaceuticals, Inc. (HEPA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 21.94K | 18.79K | 26.74K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | -21.94K▲ 0% | -18.79K▲ 14.4% | -26.74K▼ 42.3% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | 14.36% | -42.32% | 100% | - | - | - | - | - | - |
Operating Expenses | 21.02M | 14.59M | 7.77M | 20.15M | 30.4M | 45.49M | 48.45M | 19.35M | 4.16M | 3.68M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 6.69M | 7M | 4.59M | 8.15M | 10.01M | 10.35M | 9.62M | 7.5M | 3.32M | 2.79M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
Research & Development | 14.33M | 7.59M | 3.18M | 12M | 20.4M | 33.27M | 35.64M | 11.85M | 445.51K | 493.28K |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | -108.94K | 0 | 0 | 0 | 1.87M | 3.19M | 0 | 402.75K | 402.75K |
Operating Income | -21.04M▲ 0% | -14.59M▲ 30.6% | -7.77M▲ 46.8% | -20.15M▼ 159.3% | -30.4M▼ 50.9% | -45.49M▼ 49.6% | -48.45M▼ 6.5% | -19.35M▲ 60.1% | -4.16M▲ 78.5% | -3.68M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | -0.09% | 30.65% | 46.76% | -159.28% | -50.91% | -49.62% | -6.51% | 60.07% | 78.48% | - |
EBITDA | -21.02M | -14.58M | -7.74M | -20.11M | -30.32M | -45.41M | -48.38M | -19.32M | -8.25M | -3.68M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | -0.12% | 30.66% | 46.87% | -159.73% | -50.75% | -49.79% | -6.54% | 60.08% | 57.27% | 76.72% |
D&A (Non-Cash Add-back) | 21.94K | 18.79K | 26.74K | 34.52K | 86.07K | 77.46K | 67.13K | 30.76K | 0 | 0 |
EBIT | -18.92M | -14.59M | -7.77M | -20.15M | -32.71M | -45.07M | -49.33M | -14.91M | -8.25M | -2.97M |
Net Interest Income | 0 | 0 | -555K | -31.23K | -8.86K | -10.16K | -9.46K | -1.25M | -24.41K | -22.82K |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 339.16K | 555K | 31.23K | 8.86K | 10.16K | 9.46K | 1.25M | 24.41K | 22.82K |
Other Income/Expense | 2.13M | 4.61M | -175.94K | -177.28K | -2.32M | 404.83K | -887.11K | 3.18M | -4.11M | 698.85K |
Pretax Income | -18.92M▲ 0% | -9.99M▲ 47.2% | -7.95M▲ 20.4% | -20.32M▼ 155.8% | -32.72M▼ 61.0% | -45.08M▼ 37.8% | -49.34M▼ 9.4% | -16.16M▲ 67.2% | -8.28M▲ 48.8% | -2.98M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
Income Tax | -3.9M | -536K | -908.68K | 30.58K | 0 | -2.88M | -409.02K | -2.97M | 0 | 0 |
Effective Tax Rate % | 20.59% | 5.37% | 11.44% | -0.15% | 0% | 6.4% | 0.83% | 18.37% | 0% | 0% |
Net Income | -15.02M▲ 0% | -9.45M▲ 37.1% | -7.04M▲ 25.5% | -20.35M▼ 189.2% | -32.72M▼ 60.8% | -42.2M▼ 29.0% | -48.93M▼ 15.9% | -13.19M▲ 73.0% | -8.28M▲ 37.3% | -2.98M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - | - |
Net Income Growth % | -0.88% | 37.1% | 25.53% | -189.23% | -60.77% | -28.96% | -15.94% | 73.04% | 37.25% | 81.86% |
Net Income (Continuing) | -15.02M | -9.45M | -7.04M | -20.35M | -32.72M | -42.2M | -48.93M | -13.19M | -8.28M | -2.98M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -106400.00▲ 0% | -97353.00▲ 8.5% | -6108.07▲ 93.7% | -2103.70▲ 65.6% | -465.52▲ 77.9% | -594.75▼ 27.8% | -616.07▼ 3.6% | -107.35▲ 82.6% | -0.88▲ 99.2% | -0.26▲ 0% |
EPS Growth % | -3053.59% | 8.5% | 93.73% | 65.56% | 77.87% | -27.76% | -3.58% | 82.58% | 99.18% | 99.69% |
EPS (Basic) | -106400.00 | -97353.00 | -6108.07 | -2103.70 | -465.52 | -594.75 | -616.07 | -107.35 | -0.88 | - |
Diluted Shares Outstanding | 138 | 184 | 2.04K | 9.68K | 70.29K | 76.23K | 79.42K | 122.89K | 9.41M | 11.62M |
Basic Shares Outstanding | 138 | 184 | 2.04K | 9.68K | 70.29K | 76.23K | 79.42K | 122.89K | 9.41M | 11.62M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
HEPA Balance Sheet
Hepion Pharmaceuticals, Inc. (HEPA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 6.06M | 2.97M | 14.39M | 42.63M | 97.45M | 56.5M | 17.49M | 1.61M | 3.07M | 2.71M |
Cash & Short-Term Investments | 5.95M | 2.83M | 13.92M | 40.73M | 91.35M | 51.19M | 14.79M | 406.41K | 1.83M | 2.6M |
Cash Only | 5.95M | 2.83M | 13.92M | 40.73M | 91.35M | 51.19M | 14.79M | 406.41K | 1.83M | 2.6M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Non-Current Assets | 5.19M | 5.22M | 6.22M | 6.01M | 6.1M | 3.75M | 606.56K | 0 | 0 | 0 |
Property, Plant & Equipment | 56.59K | 32.43K | 855.08K | 664.93K | 456.46K | 3.32M | 242.37K | 0 | 0 | 0 |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | - |
Goodwill | 1.87M | 1.87M | 1.87M | 1.87M | 1.87M | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 3.19M | 3.19M | 3.19M | 3.19M | 3.19M | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | -731.3K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 3.26M | 127.79K | 306.88K | 285.1K | 582.85K | -2.76M | 364.19K | 0 | 0 | 0 |
Total Assets | 11.25M▲ 0% | 8.19M▼ 27.2% | 20.61M▲ 151.7% | 48.65M▲ 136.0% | 103.55M▲ 112.9% | 60.24M▼ 41.8% | 18.09M▼ 70.0% | 1.61M▼ 91.1% | 3.07M▲ 90.2% | 2.71M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | -38.79% | -27.23% | 151.69% | 136.01% | 112.87% | -41.82% | -69.97% | -91.08% | 90.24% | 8.7% |
Total Current Liabilities | 2.6M | 2.85M | 1.61M | 4.66M | 8.21M | 7.89M | 5.29M | 3.14M | 299.38K | 735.57K |
Accounts Payable | 1.56M | 748.43K | 491.56K | 3.72M | 2.45M | 2.67M | 2.35M | 220.2K | 167.81K | 138.44K |
Days Payables Outstanding | 25.9K | 14.54K | 6.71K | - | - | - | - | - | - | - |
Short-Term Debt | 0 | 1.44M | 0 | 0 | 0 | 0 | 0 | 2.9M | 54.07K | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 2.99M | 2.27M | 386K | 0 | 0 | 597.13K |
Current Ratio | 2.33x | 1.04x | 8.94x | 9.15x | 11.88x | 7.16x | 3.31x | 0.51x | 10.25x | 3.68x |
Quick Ratio | 2.33x | 1.04x | 8.94x | 9.15x | 11.88x | 7.16x | 3.31x | 0.51x | 10.25x | 3.68x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 4.95M | 3.36M | 3.39M | 3.46M | 2.35M | 2.5M | 5.52M | 333.19K | 103.02K | 113.17K |
Long-Term Debt | 0 | 0 | 0 | 176.59K | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 540.75K | 295.75K | 50.34K | 0 | 93.1K | 0 | 0 | 0 |
Deferred Tax Liabilities | 896.7K | 360.7K | 409.02K | 409.02K | 0 | 409.02K | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4.05M | 3M | 2.44M | 2.58M | 2.3M | 2.09M | 5.43M | 333.19K | 103.02K | 113.17K |
Total Liabilities | 7.55M | 6.21M | 4.99M | 8.12M | 10.56M | 10.39M | 10.81M | 3.48M | 402.4K | 848.75K |
Total Debt | 0 | 1.44M | 807.45K | 752.17K | 316.99K | 53.61K | 209.02K | 2.9M | 54.07K | 0 |
Net Debt | -5.95M | -1.39M | -13.12M | -39.97M | -91.03M | -51.14M | -14.58M | 2.49M | -1.77M | -2.6M |
Debt / Equity | - | 0.73x | 0.05x | 0.02x | 0.00x | 0.00x | 0.03x | - | 0.02x | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.71x |
Interest Coverage | - | -43.03x | -14.00x | -645.11x | -3692.66x | -4434.65x | -5211.37x | -11.96x | -338.17x | -130.18x |
Total Equity | 3.7M▲ 0% | 1.98M▼ 46.7% | 15.62M▲ 690.7% | 40.52M▲ 159.5% | 93M▲ 129.5% | 49.86M▼ 46.4% | 7.28M▼ 85.4% | -1.86M▼ 125.6% | 2.67M▲ 243.2% | 1.86M▲ 0% |
Equity Growth % | -59.12% | -46.67% | 690.7% | 159.47% | 129.5% | -46.39% | -85.4% | -125.59% | 243.16% | 1114.86% |
Book Value per Share | 26783.65 | 10741.04 | 7644.00 | 4187.29 | 1323.00 | 654.03 | 91.68 | -15.16 | 0.28 | 0.16 |
Total Shareholders' Equity | 3.7M | 1.98M | 15.62M | 40.52M | 93M | 49.86M | 7.28M | -1.86M | 2.67M | 1.86M |
Common Stock | 7.83K | 25 | 375 | 3.2K | 7.62K | 381 | 482 | 14 | 1.16K | 1.16K |
Retained Earnings | -67.01M | -76.46M | -83.75M | -104.11M | -133.5M | -175.7M | -224.63M | -237.82M | -246.1M | -246.91M |
Treasury Stock | 6.85K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | -90.17K | -78.78K | 8.35K | 8.35K | 8.35K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HEPA Cash Flow Statement
Hepion Pharmaceuticals, Inc. (HEPA) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -8.21M | -15.65M | -7.57M | -16.17M | -31.22M | -34.96M | -40.89M | -18.22M | -3.27M | -1.58M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | 57.18% | -90.59% | 51.65% | -113.68% | -93.16% | -11.97% | -16.96% | 55.45% | 82.04% | 392.62% |
Net Income | -15.02M | -9.45M | -7.04M | -20.35M | -32.72M | -42.2M | -48.93M | -13.19M | -8.28M | -2.98M |
Depreciation & Amortization | 21.94K | 18.79K | 26.74K | 34.52K | 86.07K | 77.46K | 67.13K | 30.76K | 0 | 0 |
Stock-Based Compensation | 1.57K | 234.51K | 66.18K | 2.38M | 4.67M | 2.55M | 1.34M | 791.64K | 20.78K | 0 |
Deferred Taxes | -372.92K | -536K | 48.32K | 0 | 0 | 0 | -409.02K | 0 | 0 | 0 |
Other Non-Cash Items | 7.34M | -4.94M | 157.28K | 146.05K | 2.31M | 1.46M | 4.07M | -3.16M | 4.49M | -1.2M |
Working Capital Changes | -19.21K | -970.48K | -826.23K | 1.63M | -5.57M | 3.15M | 2.97M | -2.68M | 493.05K | 1.79M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -111.21K | -897.7K | -317.05K | 0 | -1.07M | 0 | 0 | 0 | 0 | 352.47K |
Cash from Investing | -2 | 900 | -51.47K | -85.79K | -130.41K | -14.07K | -14.3K | -600K | -132.12K | -132.12K |
Capital Expenditures | -2 | 0 | -51.47K | -87.98K | -130.41K | -16.34K | -14.3K | 0 | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 900 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 1 | 0 | 2.19K | 0 | 2.27K | 0 | -600K | 0 | -132.12K |
Cash from Financing | 1.18M | 12.52M | 18.71M | 43.05M | 81.98M | -5.14M | 4.49M | 4.35M | 4.83M | -276.18K |
Debt Issued (Net) | 0 | 1.33M | -1.12M | 176.59K | -176.59K | 0 | 0 | 0 | -3.37M | -368.82K |
Equity Issued (Net) | 1.18M | 12.05M | 17.74M | 42.87M | 82.15M | -3.14M | 0 | 2.5M | 9M | 0 |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 11.9M | -857.4K | 2.09M | 12K | 0 | -2M | 4.49M | 1.85M | -802.6K | 92.65K |
Net Change in Cash | -1.45M▲ 0% | -3.12M▼ 115.3% | 11.09M▲ 455.3% | 26.8M▲ 141.7% | 50.62M▲ 88.9% | -40.16M▼ 179.3% | -36.4M▲ 9.4% | -14.38M▲ 60.5% | 1.42M▲ 109.9% | -1.98M▲ 0% |
Free Cash Flow | -8.21M▲ 0% | -15.65M▼ 90.6% | -7.62M▲ 51.3% | -16.25M▼ 113.4% | -31.35M▼ 92.9% | -34.98M▼ 11.6% | -40.9M▼ 16.9% | -18.22M▲ 55.5% | -3.27M▲ 82.0% | -1.58M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - | - |
FCF Growth % | 57.21% | -90.59% | 51.32% | -113.39% | -92.92% | -11.55% | -16.94% | 55.46% | 82.04% | 89.98% |
FCF per Share | -59374.94 | -85088.71 | -3728.11 | -1679.57 | -446.07 | -458.85 | -515.05 | -148.23 | -0.35 | -0.14 |
FCF Conversion (FCF/Net Income) | 0.55x | 1.66x | 1.07x | 0.79x | 0.95x | 0.83x | 0.84x | 1.38x | 0.40x | 0.53x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 941 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HEPA Key Ratios
Hepion Pharmaceuticals, Inc. (HEPA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -235.44% | -332.83% | -80.01% | -72.52% | -49.02% | -59.08% | -171.26% | -487.03% | -2058.63% | -102.45% |
Return on Invested Capital (ROIC) | - | -1878.68% | -377.95% | -991.8% | -1817.84% | -9983.03% | - | -2302.24% | -409.86% | -423.24% |
Debt / Equity | - | 0.73x | 0.05x | 0.02x | 0.00x | 0.00x | 0.03x | - | 0.02x | 0.00x |
Interest Coverage | - | -43.03x | -14.00x | -645.11x | -3692.66x | -4434.65x | -5211.37x | -11.96x | -338.17x | -130.18x |
FCF Conversion | 0.55x | 1.66x | 1.07x | 0.79x | 0.95x | 0.83x | 0.84x | 1.38x | 0.40x | 0.53x |
Related:HEPA Dividend History·HEPA Revenue History·HEPA Price History·HEPA P/E History·HEPA Financial Ratios·HEPA Institutional Holders
HEPA SEC Filings & Documents
Hepion Pharmaceuticals, Inc. (HEPA) SEC filings — annual & quarterly reports (10-K, 10-Q)
HEPA Frequently Asked Questions
Hepion Pharmaceuticals, Inc. (HEPA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Hepion Pharmaceuticals, Inc. (HEPA) grew revenue by 0.0% over the past year. Growth has been modest.
Hepion Pharmaceuticals, Inc. (HEPA) reported a net loss of $3.0M for fiscal year 2025.
Dividend & Returns
Hepion Pharmaceuticals, Inc. (HEPA) has a return on equity (ROE) of -2058.6%. Negative ROE indicates the company is unprofitable.
Hepion Pharmaceuticals, Inc. (HEPA) had negative free cash flow of $1.6M in fiscal year 2025, likely due to heavy capital investments.